Neos Therapeutics
Neos Therapeutics, Inc.
2940 N. Hwy 360, Suite 400
Grand Prairie, TX 75050
Phone: (972) 408-1300Website: https://www.neostx.com/Careers: www.neostx.com/careers
Latest news
- Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER (amphetamine) Extended-Release Oral Suspension for ADHD
15 September 2017 - Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
19 June 2017 - Neos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHD
20 December 2016 - Neos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, NT-0201, for the Treatment of ADHD
17 November 2016 - Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT (Amphetamine Extended-Release Orally Disintegrating Tablet) for ADHD
27 January 2016 - Neos Therapeutics Receives Complete Response Letter From the FDA for Cotempla XR-ODT
10 November 2015 - Neos Therapeutics Announces Submission of NDA for its Methylphenidate Extended Release Oral Disintegrating Tablet (XR-ODT) for the Treatment of ADHD
12 January 2015
Drugs Associated with Neos Therapeutics, Inc.
Neos Therapeutics, Inc. manufactures, markets and/or distributes more than 4 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Adzenys ER
Generic name: amphetamine Drug class: CNS stimulants |
1 review | 8.0 / 10 |
|
Adzenys XR-ODT
Generic name: amphetamine Drug class: CNS stimulants |
59 reviews | 6.1 / 10 |
|
chlorpheniramine/hydrocodone
Generic Drug class: upper respiratory combinations |
123 reviews | 9.2 / 10 |
|
Cotempla XR-ODT
Generic name: methylphenidate Drug class: CNS stimulants |
8 reviews | 6.5 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
